Top 5 Shipping Stocks To Own Right Now

The government of Indonesia in January banned the export of all raw materials and then introduced an escalating export tax of 20% to 25% on copper concentrate sent out of the country. The tax would increase to 60% by 2016. The clear intent is to force copper miners to process raw materials and build smelters in Indonesia to move the country up the value chain.

The country�� two largest copper miners, Freeport-McMoRan Copper & Gold Inc. (NYSE: FCX) and Newmont Mining Corp. (NYSE: NEM) have refused to pay the new tax claiming that it violates their existing contracts. The government backed off a bit last week, saying that it would ��onsider reducing the duty for miners who are ��erious��about smelting their mineral concentrates in the country before shipping the metals to buyers abroad,��according to report in The Wall Street Journal.

Freeport said last week it may declare force majeure if it cannot resolve the dispute, but it has also told the government that it is ��erious��about building a smelter in Indonesia. The company has not exported any copper concentrate since mid-January.

Top 5 Defense Stocks To Watch For 2015: Liberty Global Inc. (LBTYK)

Liberty Global, Inc. provides video, broadband Internet, and telephony services primarily in Europe and Chile. The company offers broadband services over cable distribution systems, including video, broadband Internet, and telephony; and video services through direct-to-home satellite, or through multichannel multipoint distribution systems. Its analog video services comprise basic and expanded basic programming; and digital cable services include basic and premium programming, digital video recorders, and high definition programming, as well as pay-per-view programming, such as video-on-demand and near video-on-demand. In addition, the company offers voice-over-Internet-protocol and circuit-switched telephony services, as well as mobile telephony services using third-party networks. Further, it owns programming networks that provide video programming channels to multi-channel distribution systems owned by the company and the third parties. As of December 31, 2011, the com pany owned and operated networks that passed 33,262,100 homes; and served 18,405,500 video subscribers, 8,159,300 broadband Internet subscribers, and 6,225,300 telephony subscribers. Liberty Global, Inc. was founded in 2004 and is based in Englewood, Colorado.

Advisors' Opinion:

• [By GuruFocus]

  Warren Buffett (Trades, Portfolio) added to his holdings in Liberty Global PLC by 149.19%. His purchase prices were between $40.36 and $45.96, with an estimated average price of $43.34. The impact to his portfolio due to this purchase was 0.17%. His holdings were 7,346,968 shares as of 03/31/2014.

  Added: Liberty Global PLC (LBTYK)

  Warren Buffett (Trades, Portfolio) added to his holdings in Liberty Global PLC by 149.19%. His purchase prices were between $38.905 and $43.46, with an estimated average price of $41.33. The impact to his portfolio due to this purchase was 0.17%. His holdings were 7,346,968 shares as of 03/31/2014.

• [By Monica Wolfe]

  Liberty Global PLC (LBTYK)

  John Burbank upped his stake by 376.63% during the second quarter. The guru purchased a total of 402,991 shares in the second quarter price range of $64.57 to $73.78, with an estimated average price of $69.23 per share. Since then the price per share has increased approximately 4.9%.

Top 5 Shipping Stocks To Own Right Now: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Russ Krull]

  Finally, Ireland-based biotech Elan (NYSE: ELN  ) issued $850 million of eight-year notes. The money is going to help pay for a royalty stake in some Theravance products. Elan expects the transaction to add to earnings starting in 2014. My Foolish colleagues Sean Williams and Brian Orelli think this might be a better deal for Theravance than for Elan.

• [By Brian Orelli]

  Royalty Pharma announced Monday that it's willing increase the $11-per-share offer it made for Elan (NYSE: ELN  ) back in February, depending on the result of Elan's buyback.

• [By WALLSTCHEATSHEET]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with neurodegenerative and autoimmune diseases. The stock has struggled over the last couple of years and looks to be comfortable at these prices. Over the last four quarters, investors in the company have been disappointed as earnings have decreased while revenue figures have increased. Relative to its peers and sector, Elan has been a year-to-date performance leader. WAIT AND SEE what Elan does in coming quarters.

• [By Brian Orelli]

  Johnson & Johnson (NYSE: JNJ  ) is the leader for the long-acting antipsychotic, selling $1.4 billion worth of Risperdal Consta and $800 million worth of Invega Sustenna last year. Alkermes (NASDAQ: ALKS  ) also benefits from a royalty on both drugs. It developed the extended-release technology in Risperdal Consta, and Alkermes acquired the royalty rights to Invega Sustenna when it bought Elan's (NYSE: ELN  ) drug technology division.

Top 5 Shipping Stocks To Own Right Now: Scripps Networks Interactive Inc(SNI)

Scripps Networks Interactive, Inc. operates as a lifestyle content company in the United States and internationally. It engages in the operation of television networks, including Home and Garden Television, Food Network, Travel Channel, DIY Network, Cooking Channel, and Great American Country. The company also operates Websites, including FoodNetwork.com, Food.com, CookingChannelTV.com, HGTV.com, DIYnetwork.com, and Travelchannel.com that are associated with its television networks and other Internet-based businesses serving food, home, and travel related categories. Scripps Networks Interactive, Inc. is headquartered in Knoxville, Tennessee.

Advisors' Opinion:

• [By Will Ashworth]

  Somebody will buy Scripps Networks Interactive (SNI), given that HGTV and Food Network are both in the top 20. It looked momentarily like Discovery Communications (DISCA) might be the suitor, but the company backed out of talks this past week, preferring to focus on overseas expansion.

Top 5 Shipping Stocks To Own Right Now: Algonquin Power & Utilities Corp (AQN)

Algonquin Power & Utilities Corp. (APUC) is engaged in ownership of power generation facilities and water, gas and energy utilities, through investments in securities of subsidiaries, including companies, limited partnerships and trusts. It operates in two segments: APCo, which owns or has interests in renewable energy facilities and thermal energy facilities, and Liberty Utilities, which owns and operates utilities in the United States of America providing water, wastewater and local electric distribution services. In February 2013, it acquired the regulated water distribution utility assets located in Pine Bluff, Arkansas from United Waterworks Inc. Effective December 20, 2013, Algonquin Power & Utilities Corp. announced that, Liberty Utilities, APUC's regulated distribution utility, acquired the Massachusetts natural gas distribution utility assets (New England Gas Assets) of Southern Union Company, a wholly owned indirect subsidiary of Energy Transfer Partners, L.P. Advisors' Opinion:

• [By Eric Lam]

  Algonquin Power & Utilities Corp. (AQN) increased 3.7 percent to C$6.94 after Sean Steuart, analyst with TD Securities, raised his rating for the stock to buy from hold. Algonquin owns and invests in renewable power assets across North America.